| Selective PPAR agonists for the treatment of type 2 diabetes. | |
| | |
MedLine Citation:
|
PMID: 16804025 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Type 2 diabetes is a metabolic disease characterized by increased plasma glucose and insulin as well as dyslipidemia. If left untreated, chronic diseases will develop that are associated with neuropathic damage and higher mortality risk. Using a rational drug design, novel compounds have been developed that selectively activate the human PPAR receptors, leading to lessening of hyperglycemia and hyperinsulinemia as well as reduction of lipid levels in conjunction with an increase of the beneficial HDL-cholesterol. These PPAR agonists showed increased potency and efficacy compared to previously marketed insulin sensitizers. Lead compounds with desirable pharmacokinetic properties were chosen for further testing in several animal models. The in vivo activity of some synthetic ligands, capable of activating two or all three members of peroxisome proliferator-activated receptors (PPAR) family of receptors, suggested that they may have improved efficacy in type 2 diabetes therapy. Here, we briefly summarize the development of some novel PPAR agonists identified by our group in recent years. |
| | |
Authors:
|
Jan O Nehlin; John P Mogensen; Ingrid Petterson; Lone Jeppesen; Jan Fleckner; Erik M Wulff; Per Sauerberg |
Related Documents
:
|
3899815 - Influence of fasting and refeeding on the antilipolytic effect of insulin in human fat ... 21427735 - Are the glycemic and insulinemic index values of carbohydrate foods similar in healthy ... 3552635 - Adenosine modulates insulin activation of insulin receptor kinase in intact rat adipocy... 18287215 - Effect of chronic endothelin receptor antagonism on cerebrovascular function in type 2 ... 7204315 - Free sugars and sorbitol in fruits--a complication from the literature. 4591035 - Cholinergic modification of glucose-induced biphasic insulin release in vitro. |
Publication Detail:
|
Type: Journal Article; Review |
Journal Detail:
|
Title: Annals of the New York Academy of Sciences Volume: 1067 ISSN: 0077-8923 ISO Abbreviation: Ann. N. Y. Acad. Sci. Publication Date: 2006 May |
Date Detail:
|
Created Date: 2006-06-28 Completed Date: 2006-07-18 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 7506858 Medline TA: Ann N Y Acad Sci Country: United States |
Other Details:
|
Languages: eng Pagination: 448-53 Citation Subset: IM |
Affiliation:
|
Novo Nordisk A/S, Måløv, Denmark. jan.nehlin@ouh.fyns-amt.dk |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Animals Diabetes Mellitus, Type 2 / drug therapy* Dyslipidemias / drug therapy Humans Hyperglycemia / drug therapy Hypoglycemic Agents / therapeutic use Insulin / therapeutic use Models, Biological Peroxisome Proliferator-Activated Receptors / agonists*, classification, physiology |
| Chemical | |
Reg. No./Substance:
|
0/Hypoglycemic Agents; 0/Peroxisome Proliferator-Activated Receptors; 11061-68-0/Insulin |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Heat shock-induced enhancement of osteoblastic differentiation of hTERT-immortalized mesenchymal ste...
Next Document: Alzheimer's disease pathogenesis: role of aging.